-
Imperial College: Temperature increase can reduce the spread of the new coronavirus, but control measures still need to be taken
Time of Update: 2021-06-16
It has been difficult to quantify the impact of environmental factors such as temperature, humidity, and ultraviolet radiation (sunlight) on the spread of SARS-CoV-2, because human factors such as population density and behavior have been the main drivers of transmission .
-
Taiwan's high-end vaccine announced the data of the second phase test, the seroconversion rate of 28 days after the second dose reached 99.8%?
Time of Update: 2021-06-16
It was announced that the high-end vaccine (Medigen Vaccine Biologics) from Taiwan’s biopharmaceutical company Corp) developed the new coronary pneumonia vaccine phase II clinical trial analysis data showed that: safety and tolerability are good, all subjects did not have vaccine-related serious adverse reactions; in the immunogenic part, the vaccine does not distinguish between age groups.
-
JAMA: Vaccination and previous infections can reduce the risk of positive SARS-CoV-2 PCR test
Time of Update: 2021-06-16
Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar.
Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar.
-
Innovative drugs solve the multiple myeloma drug resistance problem with a total remission rate of 73%!
Time of Update: 2021-06-12
Recently, the US FDA granted the bispecific antibody Teclistamab (JNJ-7957) breakthrough therapy designation for the treatment of patients with relapsed/refractory multiple myeloma (MM).
In the past two years, the FDA has approved many new therapies, including Abecma, a CAR-T therapy targeting BCMA, and Blenrep, an antibody-conjugated drug, for the treatment of patients with relapsed/refractory MM.
-
"Pharmaceutical Speed Reading Club" Jimin Pharmaceutical changed its name to Jimin Medical Shengnuo Biotechnology Innovation Board
Time of Update: 2021-06-12
[June 3, 2021/Medical Information List] GlaxoSmithKline's Zofran safety lawsuit was won; Jiangxi started its first municipal mass purchase; Roche's "Otuzumab" was approved for listing in China.
-
The FDA approves the first new class of antifungal drug Brexafemme Hausen...
Time of Update: 2021-06-12
Recently, Synexis, a partner of Hausen Pharmaceuticals, announced that the US Food and Drug Administration has approved a new broad-spectrum antifungal drug Brexafemme, which is an oral drug for the treatment of female patients with vulvovaginal candidiasis.
-
Focus on eliminating hepatitis hazards and improve the availability of innovative drugs
Time of Update: 2021-06-12
Viral hepatitis is an important public health problem that endangers human health. my country has made great achievements in preventing new hepatitis infections. However, according to the National
-
Office of the State Council: Strengthen the construction of clinical specialties and increase support for Chinese medicine hospitals
Time of Update: 2021-06-12
On June 4, the General Office of the State Council issued its opinions on promoting the high-quality development of public hospitals.
, and the development of specialties will promote the improvement of diagnosis and treatment capabilities and levels .
Strengthen the construction of superior specialties of traditional Chinese medicine.
-
Chinese scientist "Nature" sub-published article provides new direction for new crown antibody drug research and development
Time of Update: 2021-06-12
Recently, a study published in the internationally renowned journal Nature Communications showed that in addition to the new coronavirus S protein, the new coronavirus nucleocapsid protein (hereinafter referred to as "N protein") also has the potential to serve as a neutralizing antibody target.
-
Baiyunshan: Cefixime capsules passed the consistency evaluation of generic drugs
Time of Update: 2021-06-12
Baiyunshan Pharmaceutical General Factory received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, cefixime capsules The quality and efficacy consistency evaluation of generic drugs has been passed.
At present, domestic manufacturers of cefixime capsules also include CSPC Ouyi Pharmaceutical Co.
-
PCT guides the hierarchical management of adult lower respiratory tract infectious diseases, a list of expert consensus recommendations!
Time of Update: 2021-06-11
Plasma marker procalcitonin (PCT) helps distinguish bacterial and non-bacterial infections, and including it in the overall evaluation index of infectious diseases can provide patients with diagnosis and treatment decisions; at the same time, it can safely reduce the prescription rate of antibacterial drugs and shorten The course of anti-infective treatment reduces the rate of bacterial resistance.
-
WHO Guidelines: How to treat drug-resistant tuberculosis comprehensively?
Time of Update: 2021-06-11
The recommended evidence comes from a study showing that the use of a shorter course of bedaquiline-containing oral regimens in MDR/RR-TB patients is associated with a higher treatment success rate (AOR 2.
-
What is the effect of Sinopharm inactivated vaccine?
Time of Update: 2021-06-11
The results of the recent phase III clinical trial of Sinopharm's new crown virus inactivated vaccine were published in JAMA, and the protective effect against symptomatic new crown infection was 72.
-
2021 ASCRS Guidelines: Management of Clostridium difficile Infection
Time of Update: 2021-06-11
Recently, the American College of Colon and Rectal Surgeons (ASCRS) issued management guidelines for Clostridium difficile infection (CDI), which mainly provide guidance and recommendations for the management of Clostridium difficile infection, including evaluation, drug treatment, surgical treatment, and relapse or refractory Management of curative Clostridium difficile infection, etc.
-
The patient has high fever and is resistant to cephalosporin!
Time of Update: 2021-06-11
Only for medical professionals to read and refer to Enterobacter cloacae infection, how to choose the right antibacterial drug?
After the treatment, drug resistance of Enterobacter cloacae was detected in the abdominal drainage fluid, and the drug sensitivity result is shown in Figure 1.
-
Strongly inhibit a large number of variants of the new coronavirus! Today's "Nature" highlights the extensive protection of new antibodies
Time of Update: 2021-06-11
▲ Schematic diagram of the structure of IgG, IgA1 and IgM antibodies (picture source: Reference [1]) In this paper, the researchers used six monoclonal antibodies that can recognize different epitopes of the new coronavirus receptor binding domain (RBD).
-
The Indian mutant strain B.1.617 has increased infectivity by 50% and has spread to dozens of countries within half a year
Time of Update: 2021-06-11
Both of these mutations are related to increased infectivity and can change the use of the new coronavirus to invade Spike protein of human cells.
-
Express FDA approves the 25th new drug this year, the speed of approval hit a record high over the same period
Time of Update: 2021-06-11
▎ WuXi AppTec content team editor On June 2, 2021, Scinexis announced that the US FDA has approved the innovative oral glucan synthase inhibitor Brexafemme (ibrexafungerp) to be marketed for the treatment of vulvovaginal candidiasis (VVC, also known as For vaginal yeast infections), Brexafemme belongs to the "first-in-class" triterpene antifungal agent.
-
After 12 years, Mengke Pharmaceutical announced that Contizolamide Tablets, a new anti-drug-resistant bacteria drug, was approved for marketing
Time of Update: 2021-06-11
Mengke Pharmaceutical is about to launch an international multi-center phase III clinical trial to support the approval of Contizolamide in other countries and/or regions such as Europe and the United States.
-
A simple spray to prevent the new crown infection!
Time of Update: 2021-06-11
▎Editor of WuXi AppTec Content Team On May 26, 2021, Professor Shi Yi from the University of Pittsburgh School of Medicine (UPMC) and a collaborator at the Center for Vaccine Research of the University of Pittsburgh published an article in Science Advances, showing a A nanobody-based anti-coronavirus (SARS-CoV-2) spray therapy.
